Float Short %

30.4

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

0.16

EPS Last/This Y

0.67

EPS This/Next Y

1.31

Price

19.98

Target Price

39.31

Analyst Recom

1.07

Performance Q

25.42

Relative Volume

0.88

Beta

0.49

Ticker: SNDX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	SNDX	15.71	0.45	0.09	52608
2025-11-11	SNDX	17.72	0.46	0.16	52080
2025-11-12	SNDX	16.8	0.45	0.35	52284
2025-11-13	SNDX	16.66	0.45	0.13	52309
2025-11-14	SNDX	16.63	0.42	0.14	55006
2025-11-17	SNDX	17.21	0.42	0.68	55092
2025-11-18	SNDX	17.09	0.39	0.12	54858
2025-11-19	SNDX	16.71	0.39	0.44	54769
2025-11-20	SNDX	17.05	0.39	0.07	54689
2025-11-21	SNDX	17.44	0.39	0.32	54568
2025-11-24	SNDX	19.78	0.36	0.18	31866
2025-11-25	SNDX	19.47	0.34	0.07	33054
2025-11-26	SNDX	19.88	0.34	0.47	33209
2025-12-01	SNDX	19.12	0.36	1.64	37423
2025-12-02	SNDX	18.79	0.35	0.37	37412
2025-12-03	SNDX	19.7	0.36	0.14	37495
2025-12-04	SNDX	19.73	0.36	0.06	37716
2025-12-05	SNDX	20.32	0.32	0.07	36045
2025-12-08	SNDX	19.95	0.31	1.52	36866
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	SNDX	15.72	50.5	209.6	-3.04
2025-11-11	SNDX	17.73	52.0	201.2	-3.02
2025-11-12	SNDX	16.81	53.5	219.3	-3.02
2025-11-13	SNDX	16.65	53.5	215.1	-2.99
2025-11-14	SNDX	16.62	50.7	214.5	-3.04
2025-11-17	SNDX	17.18	50.7	211.0	-3.04
2025-11-18	SNDX	17.08	48.0	214.9	-3.04
2025-11-19	SNDX	16.71	48.0	216.4	-3.04
2025-11-20	SNDX	17.05	48.0	212.3	-3.04
2025-11-21	SNDX	17.44	48.0	212.0	-3.04
2025-11-24	SNDX	19.77	48.0	201.3	-3.04
2025-11-25	SNDX	19.45	48.0	215.8	-3.04
2025-11-26	SNDX	19.88	48.0	212.2	-3.04
2025-12-01	SNDX	19.11	47.0	217.6	-3.05
2025-12-02	SNDX	18.79	47.0	215.9	-3.05
2025-12-03	SNDX	19.71	47.0	209.7	-3.05
2025-12-04	SNDX	19.74	47.0	214.2	-3.05
2025-12-05	SNDX	20.32	47.0	211.6	-3.05
2025-12-08	SNDX	19.98	47.0	-	-3.05
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	SNDX	-6.52	4.57	26.19
2025-11-11	SNDX	-6.52	4.57	26.19
2025-11-12	SNDX	-6.52	4.57	30.14
2025-11-13	SNDX	-6.52	4.57	30.14
2025-11-14	SNDX	-6.52	4.57	30.13
2025-11-17	SNDX	-6.58	5.23	30.13
2025-11-18	SNDX	-6.58	5.23	30.13
2025-11-19	SNDX	-6.58	5.23	30.13
2025-11-20	SNDX	-7.40	5.23	30.13
2025-11-21	SNDX	-7.40	5.23	30.13
2025-11-24	SNDX	-7.40	-3.22	30.08
2025-11-25	SNDX	-7.78	-3.22	30.08
2025-11-26	SNDX	-7.78	-3.22	30.41
2025-12-01	SNDX	-7.78	-3.43	30.41
2025-12-02	SNDX	-7.78	-3.43	30.41
2025-12-03	SNDX	-7.78	-3.43	30.41
2025-12-04	SNDX	-7.78	-3.43	30.41
2025-12-05	SNDX	-7.78	-3.43	30.40
2025-12-08	SNDX	-7.83	-3.47	30.40
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.7

Avg. EPS Est. Current Quarter

-0.58

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-7.83

Institutional Transactions

-3.47

Beta

0.49

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

33.1

Max Drawdown 5-Year %

-69.9

Target Price

39.31

P/E

Forward P/E

PEG

P/S

15.57

P/B

15.04

P/Free Cash Flow

EPS

-3.62

Average EPS Est. Cur. Y

-3.05

EPS Next Y. (Est.)

-1.74

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-279.31

Relative Volume

0.88

Return on Equity vs Sector %

-296.8

Return on Equity vs Industry %

-281.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.06

EBIT Estimation

Syndax Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 270

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today

news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance

stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market

stock prices SNDX premarket after hours

ticker SNDX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SNDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y